MYGN (MYGN) Stock Price & Analysis
MYGN (MYGN) fell 1.24% to USD 3.19 as of September 8, 2026 at 05:47 UTC, according to Nexqual real-time market data.
MYGN last closed at USD 3.19; the session ranged USD 3.15–3.2 on volume of 806,164 shares. Market capitalization is —, with a 52-week range of USD 2.74–8.59 (NMS). Source: Nexqual, September 8, 2026 at 05:47 UTC.
Key Statistics (as of September 8, 2026 at 05:47 UTC)
| Price | USD 3.19 |
|---|---|
| Change | ▼ 1.24% (down) |
| Previous Close | USD 3.19 |
| Open | USD 3.19 |
| Day Range | USD 3.15 – 3.2 |
| 52-Week Range | USD 2.74 – 8.59 |
| Volume | 806,164 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (MYGN)
Nexqual's technical model rates MYGN "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 05:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.51 (neutral) |
| vs SMA50 | Below (USD 4.43) |
| MACD | -0.27 (negative) |
From MYGN's Latest SEC 10-K Filing (filed 2026-02-24)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 126.75 | ▼ 1.61% |
| ALKS | Alkermes plc | USD 46.1 | ▼ 3.39% |
| NBIX | Neurocrine Biosciences, Inc. | USD 155.64 | ▼ 1.36% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 285.6 | ▼ 0.46% |
| UTHR | United Therapeutics Corporation | USD 487.61 | ▼ 0.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:47 UTC. This page is informational and not investment advice.